Telos Capital Management Inc. Sells 262 Shares of Illumina, Inc. (NASDAQ:ILMN)

Telos Capital Management Inc. lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,281 shares of the life sciences company’s stock after selling 262 shares during the quarter. Telos Capital Management Inc.’s holdings in Illumina were worth $428,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ILMN. Trivant Custom Portfolio Group LLC grew its stake in Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina during the second quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new stake in Illumina during the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 0.8 %

Shares of NASDAQ:ILMN opened at $144.06 on Wednesday. The stock has a market cap of $22.95 billion, a P/E ratio of -17.68 and a beta of 1.15. The firm has a fifty day moving average price of $133.63 and a 200 day moving average price of $121.35. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $151.40.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the business earned $0.32 EPS. The business’s revenue was down 5.4% on a year-over-year basis. Sell-side analysts predict that Illumina, Inc. will post 3.63 EPS for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of research analyst reports. Scotiabank decreased their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. TD Cowen raised shares of Illumina from a “hold” rating to a “buy” rating and raised their target price for the stock from $126.00 to $144.00 in a report on Wednesday, August 14th. Daiwa America raised shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. Leerink Partners raised their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Barclays raised their price target on shares of Illumina from $125.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $154.33.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.